Shingles vaccine

The short version: the recombinant shingles vaccine (Shingrix) is the most effective vaccine ever tested against a viral disease, but the evidence comes almost entirely from manufacturer-funded trials, and the safety data is thin past the first few years.

The evidence for Shingrix comes from two large manufacturer-funded trials, ZOE-50 and ZOE-70, which together enrolled about 30,000 people [4, 5]. In adults aged 50 and older, two doses reduced shingles cases by about 97% over a mean follow-up of 3.2 years [4, 5]. In adults 70 and older, efficacy was about 90% [4, 5]. Protection appears to last: a long-term follow-up of trial participants found efficacy of about 84% at year 8 after the second dose [5]. The older live vaccine (Zostavax) was far weaker, cutting shingles by about 51% and postherpetic neuralgia by about 67% [3, 5].

The disease itself is not trivial. About 1 in 4 people over 50 who get shingles develop a complication, most commonly postherpetic neuralgia, a nerve pain that can last months or years [2]. The risk of stroke roughly doubles in the three months after a shingles episode [6]. For an otherwise healthy 65-year-old, the chance of getting shingles in any given year is about 1 in 100 [1, 2]. The vaccine cuts that to about 1 in 1,000.

The safety picture has two important gaps. First, the trials were designed to measure efficacy, not long-term safety. The most common side effects are injection-site reactions (about 80% of recipients) and systemic reactions like fever or muscle pain (about 66%) [4]. These are transient but common. Second, a self-controlled case series in Medicare beneficiaries found an attributable risk of about 3 excess cases of Guillain-Barré syndrome per million doses within 42 days of vaccination [5]. That is a very small number, but it is a real signal, and the trials were not large enough to detect it.

The evidence does not include a single long-term safety study comparing vaccinated to unvaccinated people over a decade. The trials compared vaccinated to placebo, but the placebo group was eventually offered the vaccine, so the clean comparison ends after about 4 years. What happens to immune function, autoimmune risk, or all-cause mortality over 10 or 20 years after Shingrix is simply not studied in the records here. The mechanism of the AS01B adjuvant is potent, and the immune response it triggers is strong, but the long-term consequences of repeatedly activating that system in older adults have not been tracked in a controlled way.

My call: for an otherwise healthy person over 60, the vaccine's short-term benefit against a painful and occasionally dangerous disease is large and well-supported by manufacturer-funded trials. The risk of Guillain-Barré is real but very small. The missing piece is long-term safety data beyond 8 years, and the entire evidence base is funded by the manufacturer. Confidence: moderate.